Dianne Whitfield Sells 4,174 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne Whitfield sold 4,174 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $279,658.00. Following the completion of the sale, the insider owned 35,028 shares of the company’s stock, valued at $2,346,876. The trade was a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Tarsus Pharmaceuticals Price Performance

TARS opened at $64.51 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The stock has a market capitalization of $2.75 billion, a P/E ratio of -39.82 and a beta of 0.55. The company’s 50-day simple moving average is $69.12 and its two-hundred day simple moving average is $70.22. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The company had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. As a group, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. raised its holdings in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after purchasing an additional 172 shares during the period. State of Wisconsin Investment Board grew its holdings in Tarsus Pharmaceuticals by 1.1% during the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after purchasing an additional 332 shares during the period. Federated Hermes Inc. grew its holdings in Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after purchasing an additional 339 shares during the period. Valeo Financial Advisors LLC increased its position in Tarsus Pharmaceuticals by 11.1% in the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after buying an additional 392 shares in the last quarter. Finally, Creative Planning increased its position in Tarsus Pharmaceuticals by 3.3% in the third quarter. Creative Planning now owns 12,367 shares of the company’s stock worth $735,000 after buying an additional 393 shares in the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.